People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Biotechnology, Other Technology, Medical Devices, Healthtech, Biotech, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| JumpCode Genomics, Inc. | — | Biotechnology | Series B | $38.7M | $23.4M | 2018 |
| Ellipsis Research Inc. | — | Other Technology | Series B | $23.0M | $210.2M | 2023 |
| Prescient Surgical, Inc. | — | Medical Devices | Series A | $15.6M | $3.5M | 2017 |
| Fresca Medical, Inc. | — | Healthtech | Seed | $7.3M | $50.0M | 2014 |
| Poynt Corp | — | Other Technology | Series A | $6.3M | $158.4M | 2009 |
| iGenomX International Genomics Corp | — | Biotech | Seed | $5.1M | $66.7M | 2015 |
| Microfabrica Inc | — | Other Technology | Seed | $3.0M | $102.2M | 2011 |
| Mkango Resources Ltd. | — | Other | Seed | $3.0M | $55.1M | 2014 |
| Fathom Nickel Inc. | — | Other | Seed | $1.1M | $15.2M | 2021 |
Eugene Chen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Eugene Chen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Keith Brown | 2 | 8 |
| Kevin Li | 2 | 4 |
| Joel Rotroff | 2 | 2 |
| Bruce Feuchter | 1 | 12 |
| Brant Heise | 1 | 10 |
| Michael Liang | 1 | 9 |
| Martin J. Waters | 1 | 9 |
| John Morgan | 1 | 9 |
| George Wallace | 1 | 8 |
| Warren Packard | 1 | 7 |
| Eric Miller | 1 | 7 |
| Michael Sweeney | 1 | 7 |
| Court Turner | 1 | 6 |
| Kevin Wasserstein | 1 | 5 |
| Andrew Cragg | 1 | 5 |
| David Berg | 1 | 5 |
| Marvin Igelman | 1 | 4 |
| Dan Kidle | 1 | 4 |
| Lawrence Lee | 1 | 4 |
| CRAIG BENTHAM | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.